Cholera toxin (CT) elicits a mucosal immune response in mice when used as a vaccine adjuvant. The mechanisms by which CT exerts its adjuvant effects are incompletely understood. We show that protection against inhalation anthrax by an irradiated spore vaccine depends on CT-mediated induction of IL-17-producing CD4 Th17 cells. Furthermore, IL-17 is involved in the induction of serum and mucosal antibody responses by CT. Th17 cells induced by CT have a unique cytokine profile compared with those induced by IL-6 and TGF-β, and their induction by CT requires cAMP-dependent secretion of IL-1β and β-calcitonin gene-related peptide by dendritic cells. These findings demonstrate that Th17 cells mediate mucosal adjuvant effects of CT and identify previously unexplored pathways involved in Th17 induction that could be targeted for development of unique mucosal adjuvants.
Cholera toxin (CT) elicits a mucosal immune response in mice when used as a vaccine adjuvant. The mechanisms by which CT exerts its adjuvant effects are incompletely understood. We show that protection against inhalation anthrax by an irradiated spore vaccine depends on CT-mediated induction of IL-17-producing CD4 Th17 cells. Furthermore, IL-17 is involved in the induction of serum and mucosal antibody responses by CT. Th17 cells induced by CT have a unique cytokine profile compared with those induced by IL-6 and TGF-β, and their induction by CT requires cAMP-dependent secretion of IL-1β and β-calcitonin gene-related peptide by dendritic cells. These findings demonstrate that Th17 cells mediate mucosal adjuvant effects of CT and identify previously unexplored pathways involved in Th17 induction that could be targeted for development of unique mucosal adjuvants.
IL-17 | dendritic cell | T cell | vaccine | cAMP C holera toxin (CT), an exotoxin produced by Vibrio cholerae, is responsible for the diarrhea of cholera and is a potent mucosal-vaccine adjuvant in experimental animals (1) (2) (3) . After the pentameric B subunit of CT binds the GM1 ganglioside receptor, CT enters the cell and its catalytic-A subunit ADP ribosylates and activates the heterotrimeric guanine nucleotide bindingprotein G s , which then stimulates cAMP production by adenylyl cyclase. In intestinal epithelial cells, cAMP induces chloride secretion, leading to the massive fluid loss that characterizes cholera (4) . The toxicity of CT prevents its use as an adjuvant in humans, but understanding the mechanisms underlying its adjuvant activity may lead to development of nontoxic mucosal adjuvants for clinical use.
In contrast to what is known about the ability of CT to stimulate intestinal ion transport, the mechanisms by which CT elicits a mucosal immune response are incompletely understood. CT is typically classified as a "Th2 adjuvant" because it induces Th2-associated cytokines and antibodies, and can either induce or inhibit a Th1 response (2, 5, 6) . Th17 cells are a recently identified subset of CD4 T cells that secrete IL-17 (also known as IL-17A), are induced by IL-6 in the context of TGF-β (7-9), and play an important role in autoimmunity and the control of certain extracellular pathogens, in particular at mucosal sites (10) . In light of their important role in mucosal immunity, we hypothesized that Th17 cells may contribute to the mucosal adjuvant effects of CT. Indeed, a recent report identified the ability of CT to induce Th17 cells (11) , although the role of these cells in mediating the adjuvant effects of CT remains unresolved.
We show here that Th17 cells are required to mediate the adjuvant effects of CT. We developed an intranasal vaccine against inhalation anthrax using inactivated bacterial spores, and found that protection by this vaccine depends on induction of Th17 cells by CT. Dissection of the mechanism underlying Th17 induction by CT revealed a panel of gene products, in addition to IL-6, which contribute to Th17 differentiation. Furthermore, we found that IL-17 deficiency impairs the antibody response elicited by CT. These results suggest IL-17 plays a central role in the mucosal adjuvant activity of CT, and identify previously unexplored pathways involved in the regulation of Th17 responses that could be targeted for mucosal adjuvant development.
Results

IL-17
Contributes to the Mucosal Adjuvant Activity of CT. We first identified the IL-17-dependent adjuvant activity of CT when developing a spore-based anthrax vaccine. The currently available anthrax vaccine uses alum as an adjuvant and depends on antibody to the anthrax protective antigen (PA) (12) . Based on the sensitivity of anthrax spores to γ-irradiation (13, 14) and our recent data highlighting the immunogenic properties of a γ-irradiated bacterial vaccine (15), we used irradiated anthrax spores to immunize A/J mice against a model of inhalation anthrax. Irradiated spore-vaccine preparations derived from bacteria that either contained or lacked the gene encoding PA protected against challenge with the toxin-producing Sterne strain (Fig. 1A) . Vaccine efficacy required addition of the mucosal adjuvant, CT (Fig. 1A) .
T-cell depletion and serum transfer studies done in immunized mice at the time of infectious challenge indicated that CD4 T cells were critical during the effector phase of protection ( Fig.  1B and Fig. S1 ). Mucosal immunization with CT and irradiated anthrax spores induced spore-specific CD4 T cells that produced IL-17 but not IFN-γ, IL-5, or IL-10 ( Fig. 1C) . CT alone did not elicit this IL-17 response, indicating an antigen-specific memory response not attributable to prolonged effects of CT on cells of the innate immune system (Fig. 1C) . Antibody neutralization of IL-17, but not IFN-γ, at the time of challenge inhibited vaccinemediated protection against inhalation anthrax (Fig. 1D) . Because mice on the C57BL/6 background are not susceptible to this anthrax model, we could not use IL-17 knockout mice for these experiments, but antibody neutralization at the time of challenge allowed us to evaluate the role of IL-17 specifically in vaccine-induced effector mechanisms. C57BL/6 mice immunized either intranasally or by gavage with CT and ovalbumin (OVA) also showed similar induction of OVA-specific Th17 cells in addition to the Th2 response described in the literature (Fig. S2) . Immunization with CT plus OVA also induced an OVA-specific IL-22 response but not a detectable IL-4, IL-21, or IL-17F response (Fig. S2 ).
CT Acts on Dendritic Cells to Elicit Th17 Cells. We reasoned that CT acts on antigen-presenting cells, such as dendritic cells (DCs), to induce Th17 cells in vivo in the studies above. To test the ability of CT-treated DCs to elicit Th17 cells, we incubated C57BL/6 mouse bone marrow-derived DCs with OVA in the absence or presence of CT. The next day we added OVA-specific splenic CD4 T cells from OT-II mice. After 6 d, we restimulated the T cells. Supernatants collected 24 h after restimulation showed that CT significantly induced IL-17 and the Th17-associated cytokine IL-22, but not IFN-γ, IL-5, IL-10, or IL-21 ( Fig. 2A) .
Because CT was present when T cells were added in the experiments above, we evaluated whether CT induces IL-17 by acting via DCs or directly on T cells. Treatment of T cells with CT during stimulation by formalin-fixed, OVA-pulsed DCs did not induce IL-17 (Fig. 2B, Right bar) , similar to CT-untreated cells (Fig. 2B, Left bar) . In contrast, OVA-pulsed DCs treated with CT before fixation, and then incubated in their original CT-conditioned medium with T cells, induced IL-17 (Fig. 2B, Center bar) . Thus, CT does not act directly on T cells but instead via DCs to induce IL-17 production by T cells. Nod2 and Toll-like receptors (TLR) influence IL-17 production (9, 16). DCs from Nod2 −/− and Myd88 −/− mice retained the ability to elicit IL-17-secreting T cells after exposure to CT (Fig. 2C) . Intact IL-17 induction by Tlr4 −/− DCs further confirmed TLR-independence (Fig. 2D) .
Th17 Induction by CT Involves cAMP. We next investigated whether cAMP is involved in the DC-mediated induction of Th17 cells by CT. We found that either CT or forskolin, a direct activator of adenylyl cyclase, increased cAMP levels in DCs (Fig. 3A) . Treatment of DCs with a cell-permeant cAMP analog (8-Br-cAMP), or with agents that increase cellular cAMP [forskolin or 3-isobutyl-1-methylxanthine (IBMX), a phosphodiesterase inhibitor], mimicked the ability of CT to induce IL-17 secretion by CD4 T cells (Fig. 3B) . Treatment of DC with N6-benzoyl-cAMP, an activator of cAMP-dependent protein kinase (PKA), the major downstream effector of cAMP (17) , also induced IL-17 ( ( Fig. 3C) . Treatment of DCs with the PKA-inhibitor H89 before incubation with CT blunted the ability of CT to induce IL-17 ( Fig. 3D) . Purified CT B-subunit also had greatly reduced ability to induce IL-17 ( Fig. S3) . Taken together, these data imply that a cAMP/PKA-dependent program triggered by CT in DCs is involved in inducing IL-17 in T cells.
Th17 Differentiation by CT Depends on a Combination of Secreted
Factors. To investigate the mechanisms by which CT-treated DCs induce T-cell IL-17 production, we first determined whether induction of T-cell IL-17 by DCs requires cognate interaction via induced cell-surface molecules or depends on secreted factors. Compared with unfixed DCs (Fig. 4A , Left bars), DCs that were formalin-fixed after incubation with CT and OVA failed to induce IL-17 secretion in T cells (Fig. 4A , Center bars), indicating that cognate interaction was insufficient. Adding back supernatant from CT-treated DCs restored the ability of fixed DCs to induce IL-17 ( Fig. 4A , Right bars), implicating one or more secreted factors. Addition of medium from CT-treated DCs (CTconditioned medium, CT-CM) directly to sorted naive CD4 T cells (>99% purity) (Fig. S4A ) stimulated with anti-CD3 and anti-CD28 in the presence of neutralizing antibodies to IL-4 and IFN-γ, showed that secreted factors were sufficient to induce Th17 cells (Fig. 4B) . Consistent with prior reports (7-9), addition of IL-6 and TGF-β to this DC-free system also generated IL-17 ( Fig. 4B) . Although CT-CM generated a lower percentage of IL-17-secreting T cells compared with IL-6 and TGF-β, these cells secreted comparatively high amounts of IL-17 ( Fig. 4B and Fig.  S4B ), resulting in similar levels in the supernatant (Fig. 4C) . Naive T cells differentiated with CT-CM in this DC-free system produced IL-17 but not Th1-or Th2-related cytokines (Fig. 4D) .
CT-CM induced T cells that produced IL-22 (Fig. 4E) . However, unlike those generated by IL-6 and TGF-β, T cells differentiated with CT-CM did not produce detectable IL-21 (Fig. 4E ). Similar to IL-6 and TGF-β, CT-CM generated T cells with induced levels of the Th17-defining transcription factor RORγt (Fig. 4F) (20) . To investigate the mechanisms by which CT-CM induces Th17 differentiation, we first tested the role of factors known to influence Th17 differentiation. Blockade of IL-6 using a combination of neutralizing antibodies against IL-6 and IL-6 receptor inhibited the ability of CT-CM to induce IL-17 from naive T cells (Fig. 5A and Fig. S5A ). Blockade of TGF-β, which acts in concert with IL-6 to promote Th17 differentiation, also inhibited Th17 differentiation by CT-CM (Fig. 5A and Fig. S5A ). An antagonist of aryl hydrocarbon receptor, which is required for Th17 differentiation by IL-6 and TGF-β (21, 22) , similarly inhibited Th17 differentiation by CT-CM (Fig. S5B) . Furthermore, although IL-21 was not detectable in our previous experiments (Fig. 4E) , inhibition of IL-21 blocked IL-17 induction by CT-CM (Fig. 5A and Fig. S5A ), consistent with a critical role for low levels of this autocrine factor in amplifying Th17 cells (23) (24) (25) . Neutralization of IL-1β, which enhances Th17 differentiation (26) , also inhibited IL-17 induction by CT-CM (Fig. 5A and Fig. S5A ). Blockade of IL-23 did not affect IL-17 induction by CT-CM (Fig. 5B and Fig. S5C ), consistent with a reportedly more important role for IL-23 in the stabilization and expansion of Th17 cells than in their initial polarization (27) .
Our results confirmed the central role of IL-6 and TGF-β in mediating Th17 differentiation. However, emerging evidence suggests that other factors may act in concert with IL-6 to influence the development of Th17 cells (27) . Indeed, our results suggested CT-CM contained additional factors that conferred the phenotypic differences observed in Th17 cells induced by CT-CM compared with those induced by IL-6 and TGF-β. To identify such factors involved in Th17 induction by CT, we performed a microarray-based gene-expression analysis on DCs to detect transcripts induced after 2 h exposure to CT or forskolin, a time sufficient to induce Th17-differentiating capacity (Fig. S6 ). Based on our data implicating a cAMP-dependent mechanism, we focused on secreted gene products that were induced by both CT and forskolin (Table S1 ). These included IL-6 and IL-1β, consistent with our results above and confirmed by ELISA (Fig. S7) . Of note, TGF-β and IL-21 were not induced in DCs, a result compatible with evidence that these molecules are derived from other sources such as media supplements and T cells (27) . Microarray analysis revealed that amphiregulin, an EGF receptor ligand that activates the Th17-associated transcription factor STAT3 (28, 29), was highly induced by CT and forskolin. However, neutralizing antibodies against amphiregulin failed to inhibit Th17 differentiation by CT-CM (Fig. 5C and Fig. S5D ). CT and forskolin also induced prostaglandin endoperoxide synthase-2 (or COX-2). Prostaglandin E2, a product of COX-2 activity that increases cAMP levels in target cells, was induced in DC supernatants (Fig. S7) . Prostaglandin E2 was recently reported to augment IL-17 production by differentiated Th17 cells but not induce Th17 differentiation of naive cells in mice (30, 31) . Consistent with this, CT-CM from Cox2 −/− DCs were capable of inducing differentiation of naive T cells into Th17 cells (Fig. 5C and Fig. S5D ). Thus, amphiregulin and prostaglandins appear not to be required for CT-induced Th17 differentiation.
Microarray analysis also revealed induction of calcitoninrelated polypeptide beta (or β-calcitonin gene-related peptide, β-CGRP), a neuropeptide with described immunological properties that triggers cAMP-mediated pathways (32) . We confirmed induction of β-CGRP in DCs by CT (Fig. S7) . Addition of CGRP , a competitive antagonist of full-length β-CGRP, inhibited the ability of CT-CM to induce Th17 cells (Fig. 5D and Fig. S5E ) but had no effect on generation of Th17 cells by IL-6 and TGF-β (Fig. 5E) . Addition of full-length β-CGRP to T cells did not elicit Th17 differentiation, indicating that β-CGRP is necessary but not sufficient to induce Th17 differentiation by CT (Fig. 5D) . β-CGRP did not enhance Th17 differentiation by IL-6 and TGF-β (Fig. 5F ), but the combination of β-CGRP, IL-1β, and TGF-β in the presence of IL-23 generated Th17 cells (Fig.  5F ). Because naive T cells do not express IL-23 receptor (27) , these results are consistent with the ability of cAMP to induce IL-23 receptor (30) and suggest that β-CGRP and IL-1β can coordinate with TGF-β in the absence of IL-6 to induce a Th17 differentiation program that is then reinforced by IL-23 once its receptor is up-regulated (Fig. S8) .
CT-Induced Antibody Response Requires IL-17. A hallmark of CT is its ability to induce mucosal and systemic antibody responses. To test whether IL-17 influenced antibody production after immunization with CT, we immunized wild-type and IL-17-deficient mice either intranasally or orally with OVA or CT+OVA. Interestingly, IL-17-deficient mice showed a statistically significant impairment in mucosal IgA and systemic IgA and IgG1 production in response to CT+OVA only after oral immunization, although intranasally immunized IL-17-deficient mice did show a trend toward impaired IgA production (Fig. 6 ).
Discussion
In two experimental systems involving in vivo immunization, and in two in vitro systems that used either APC-or antibody-mediated TCR activation, we have identified IL-17 as a central mediator of the mucosal adjuvant activities of CT. Not only did IL-17 contribute to cell-mediated immunity induced after immunization with CT, but also IL-17-deficient mice had diminished antibody responses to oral immunization. This is consistent with reports that IL-17 influences B-cell activation (33), germinal center formation (34) , and up-regulation of polymeric Ig receptor (35) .
Our data identifies a role for Th17 cells in mediating protection against infection with anthrax spores. Furthermore, our results suggest a strategy for development of an anthrax vaccine that targets multiple anthrax spore antigens and does not solely depend on immunity against PA. Mechanisms required for effective acquired immunity against spores have not been previously defined, but may have important implications for vaccine development against anthrax and other spore-borne diseases. The reported activities of Th17 cells suggests they may play an important role in maintaining the epithelial barrier and recruiting local effectors, such as neutrophils and antimicrobial peptides, to contain spore-transmitted pathogens at the mucosal surface.
The current Th17 differentiation paradigm, involving IL-6, TGF-β, aryl hydrocarbon receptor, and IL-21, plays a central role in the generation of Th17 cells by CT. Indeed, a recent report observed that CT is able to generate Th17 cells in an IL-6-dependent manner (11) , and vaccines containing CT or Escherichia coli heat-labile toxin also induced IL-17 (36) (37) (38) (39) , but the mechanisms involved and the role of IL-17 in mediating adjuvant effects (i.e., antibody responses and protection against infection) were not explored. In addition, our data show that a natural biological molecule such as CT induces DCs to secrete a complex mixture of products that are required to act in combination to determine T-cell fate (Fig. S8) . The Th17 phenotype induced by this mixture of products differs from that induced by IL-6 and TGF-β, suggesting that the specific combination of factors influences the stability and characteristics of Th17 cells that are induced. The CT-CM system described, where IL-6 levels generated by CT are low (Fig. S7 ) and the use of 10% CT-CM further lowers cytokine concentrations to limiting levels, likely enhanced our ability to detect the contribution of molecules such as IL-1β and β-CGRP to Th17 differentiation by CT. Our data suggest that CT activates cAMP-dependent pathways in DCs to drive Th17 differentiation. Further studies will be needed to address whether cAMP activation in vivo is sufficient to mimic the adjuvant effects of CT. Interestingly, ATP can stimulate purinergic receptors to induce both cAMP (40) and IL-1β (41), suggesting involvement of these molecules in the ability of bacterially-derived ATP to drive Th17 responses in the gut (42) . Furthermore, the involvement of neuropeptides, such as β-CGRP and vasoactive intestinal peptide (43) in Th17 differentiation implies a role for these molecules in T-cell physiology at richly innervated locations, such as the gut mucosa.
Our findings with CT highlight the ability of this bacterial toxin to influence host immune responses beyond its contribution to bacterial virulence. Our results suggest that Th17 cells are central to the mucosal adjuvant activities of CT, likely acting to improve epithelial barrier function, recruit neutrophils, induce antimicrobial peptides, and enhance antibody production and secretion (33) (34) (35) 44) . Understanding the mechanisms by which CT exerts its mucosal adjuvant activities may identify pathways that can be targeted for development of nontoxic mucosal adjuvants and enhance our understanding of the regulation of mucosal T-cell differentiation.
Methods
Methods related to animals, reagents, ELISA, microarray analysis, PCR, and statistics are in SI Methods.
Bacterial Strains and Preparation of Spores. Bacillus anthracis Sterne (pXO1 + , pXO2 − ) has been described (45) . The PA-deficient Sterne MS1 strain (pXO1
− ) was derived by curing the pXO1 plasmid from the Sterne strain (46) .
Elimination of pXO1 was confirmed by PCR and PA immunoblot. B. anthracis spores were purified and CFUs after heat activation were determined as described (45) .
Anthrax Immunization. Purified spores (10 9 CFU/mL) were γ-irradiated with 2.27
Mrads ( 137 Cs). Loss of viability was confirmed before each vaccination by culturing 0.1 mL of the irradiated suspension for 72 h in Brain Heart Infusion broth. Anesthetized A/J mice were immunized intranasally three times at 2-week intervals with 5 × 10 7 irradiated spores and CT (1 μg). To detect cytokine production after immunization, immunized mice were challenged intranasally with 10 7 irradiated spores. Three days after challenge, we incubated isolated splenic CD4 T cells (Miltenyi Biotec) with naive A/J splenocytes that had been pulsed overnight with 10 7 irradiated spores or media alone and then treated with mitomycin C (Sigma). We collected supernatants after 3 d and measured cytokine levels by ELISA. To determine antigenspecific responses, we subtracted cytokine levels from samples that were incubated with splenocytes that had not been pulsed with irradiated spores.
Immunization with OVA. Mice were immunized intranasally with PBS, OVA (20 μg), or CT (2 μg) plus OVA (20 μg) three times at 2-week intervals. Two weeks after the last immunization, mice were killed for collection of bronchoalveolar lavage, serum, and organs. By gavage, mice were immunized on day 0 and day 14 with PBS, OVA (200 μg), or CT (20 μg) plus OVA (200 μg) in 0.1 M sodium bicarbonate. On day 39, the mice were challenged with OVA (200 μg intragastrically plus 50 μg intravenously) and then killed on day 42. Single-cell suspensions from spleens and lymph nodes were incubated for 3 d with media or OVA (200 μg/mL), and cytokine content in the supernatants was analyzed by ELISA.
In Vitro T-Cell Differentiation. Mouse bone-marrow cells were cultured for 6 d with GM-CSF (BD Biosciences) to obtain myeloid DCs (15) . The DCs were incubated with OVA and indicated stimuli. In some instances, DCs were then fixed with 2% buffered formalin without methanol (Sigma-Aldrich). Isolated CD4 + T cells (Miltenyi Biotec) from OT-II mouse spleens were then incubated with the DCs. After 6 d, the T cells were restimulated with anti-CD3 (10 μg/ mL plate-bound) and anti-CD28 (1 μg/mL soluble). For intracellular cytokine analysis, GolgiStop (BD Biosciences) was added after 2 h. After 4 additional hours, the cells were stained for the indicated cytokines before data acquisition on an LSRII or FACSCalibur flow cytometer (BD Biosciences). Data were analyzed with FlowJo software (Treestar). For ELISA analysis, the cells were restimulated for 24 h before supernatant collection.
To induce T-cell differentiation in a DC-free system, naive (CD62L high , CD44 low ) CD4 + T cells sorted by flow cytometry (>99% purity) (Fig. S4A ) from spleens of C57BL/6 mice were stimulated for 3 d with anti-CD3, anti-CD28, anti-IL-4 (10 μg/mL), and anti-IFN-γ (10 μg/mL) in the absence or presence of IL-6 (20 ng/mL), TGF-β1 (3 ng/mL), or 10% CT-CM. Other neutralizing antibodies were used at 5 to 10 μg/mL based on neutralizing activity. The T cells were expanded in fresh media containing IL-2 (5 ng/mL) for 3 additional days. Expansion with IL-23 (20 ng/mL) instead of IL-2 in select experiments gave largely similar results. The cells were then stimulated with phorbol myristate acetate (50 ng/mL) and ionomycin (1 μM) to assess cytokine production, as described above. 
